bioMerieux Buys Meikang, a China Rapid Test Manufacturer

bioMerieux (Euronext: BIM), the French maker of in vitro diagnostics, has acquired Meikang Biotech, a China company also involved in rapid test manufacturing, together with Meikang’s two hectare production site in Shanghai. bioMerieux will locate its previously announced Asia-Pacific headquarters and China R&D facility on the site. Financial terms of the acquisition were not disclosed. More details...